



Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

Soledad Henriquez, Jérémie Zerbit, Timothée Bruel, Amani Ouedrani, Delphine Planas, Paul Deschamps, Isabelle Staropoli, Jérôme Hadjadj, Bruno Varet, Natalia Ermak, et al.

► To cite this version:

Soledad Henriquez, Jérémie Zerbit, Timothée Bruel, Amani Ouedrani, Delphine Planas, et al.. Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma. *Blood*, 2022, 139 (6), pp.942-946. 10.1182/blood.2021013714 . pasteur-03696807

HAL Id: pasteur-03696807


<https://pasteur.hal.science/pasteur-03696807>

Submitted on 16 Jun 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright



TO THE EDITOR:

Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

Soledad Henriquez,^{1,*} Jérémie Zerbit,^{2,*} Timothée Bruel,^{3,4,*} Amani Ouedrani,^{5,6,*} Delphine Planas,^{3,4} Paul Deschamps,⁷ Isabelle Staropoli,³ Jérôme Hadjadj,¹ Bruno Varet,⁸ Natalia Ermak,⁹ Didier Bouscary,^{7,10} Lise Willems,⁷ Guillemette Fouquet,⁷ Justine Decroocq,⁷ Patricia Franchi,⁷ Benedicte Deau-Fischer,⁷ Benjamin Terrier,^{1,11} Jérôme Tamburini,^{7,12} Lucienne Chatenoud,^{5,6,13} Olivier Schwartz,^{3,4} and Marguerite Vignon⁷

¹Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, ²Department of Clinical Pharmacy, Assistance Publique-Hôpitaux de Paris.Centre-Université de Paris (AP-HP.CUP), Hôpital Cochin, Paris, France, ³Virus and Immunity Unit, Department of Virology, Institut Pasteur, Centre National de la Recherche Scientifique, Unité Mixte de Recherche (CNRS UMR) 3569, Paris, France, ⁴Vaccine Research Institute, Créteil, France, ⁵Department of Biological Immunology, Assistance Publique-Hôpitaux de Paris.Centre-Université de Paris (AP-HP.CUP), Hôpital Necker-Enfants Malades, Paris, France, ⁶Université de Paris, CNRS UMR 8253 and INSERM UMR 1151, Institut Necker-Enfants Malades, Paris, France, ⁷Department of Clinical Hematology, Assistance Publique-Hôpitaux de Paris.Centre-Université de Paris (AP-HP.CUP), Hôpital Cochin, Paris, France, ⁸Department of Adult Hematology, Assistance Publique-Hôpitaux de Paris.Centre-Université de Paris (AP-HP.CUP), Hôpital Necker-Enfants Malades, Paris, France, ⁹Department of Biological Immunology, Assistance Publique-Hôpitaux de Paris.Centre-Université de Paris (AP-HP.CUP), Hôpital Cochin, Paris, France, ¹⁰Université de Paris, CNRS UMR 8104, INSERM U1016, Institut Cochin, Paris, France, ¹¹Université de Paris, INSERM, U970, Paris Cardiovascular Research Center, Paris, France, ¹²Université de Genève, Couverture Maladie Universelle, Genève, France; and ¹³Université Paris Descartes, Paris, France

Multiple myeloma (MM) is considered a high-priority condition for vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).¹ The immune response to the vaccine is uncertain.² Because high titers of neutralizing antibodies (nAbs) are necessary to inhibit the delta variant of the virus,³ patients with impaired immune response may be at risk of breakthrough infection. We prospectively investigated the humoral and cellular immunologic response to anti-SARS-CoV-2 messenger RNA (mRNA) vaccine (Pfizer-BioNTech BNT162b2) in patients with MM who were receiving therapy or in whom treatment was discontinued within 12 months (from January 2021) at a single tertiary care institution in Paris.

Among 72 consecutive patients with MM, 11 had a history of previous SARS-CoV-2 infection. At the time of vaccination, 48 patients were being treated with an anti-CD38 immunotherapy-based regimen (anti-CD38 group), and 24 patients were not being treated (non-anti-CD38 group) (Figure 1A). These 2 groups were well-balanced for variables that included age, sex, International Staging System score, high-risk cytogenetics, disease duration, a history of autologous hematopoietic stem cell transplantation, and concurrent therapy with immunomodulatory imide drugs and/or proteasome inhibitors. However, patients receiving anti-CD38 therapy had more treatment lines, were more frequently remote from autologous hematopoietic stem cell transplantation, and had lower gammaglobulin levels compared with non-anti-CD38 patients (supplemental Table 1). Serum samples were collected the day before vaccination (T0), before the second dose (M1), and 1 to 2 months after completion of vaccination (M3) (see supplemental Methods). An informed signed consent was obtained from each patient in agreement with the Declaration of Helsinki. We measured the production of anti-spike (S) immunoglobulin G (IgG) and IgA and nAbs against alpha

(B.1.1.7) and delta (B.1.617.2) variants using S-Flow and S-Fuse neutralization assays, respectively.^{4,5} Moreover, we quantified the proportion of SARS-CoV-2-specific interferon- γ (IFN- γ)-producing T cells ex vivo among patient samples by using ELISpot after stimulation with S1 and S2 antigens at M3. Results obtained from samples from patients with MM were compared with those obtained from 23 healthy volunteers (control group; median age, 53 years; range, 25-73 years).

First, we focused our analysis on patients with MM who had no history of SARS-CoV-2 infection ($n = 60$) and observed that only 44% and 85% of them achieved IgG seroconversion at M1 and M3, respectively, compared with 100% among the control group (supplemental Figure 1A). Moreover, IgG and IgA titers were significantly lower at M1 in patients with MM and remained lower for IgA at M3 compared with titers in the control group (Figure 1B). Next, we observed lower IgG but similar IgA titers in patients with MM who received anti-CD38 treatment compared with those who received alternative treatments (Figure 1C; supplemental Figure 1B). To assess protection against SARS-CoV-2, we measured the production of nAbs against alpha and delta variants. nAb response was significantly higher against the alpha variant, but we observed a strong correlation between alpha and delta response across patients with MM (supplemental Figure 1C-D). Although all participants in the control group developed nAbs against both variants after vaccination, only 51% and 41% of patients with MM developed nAbs against alpha and delta variants, respectively, and alpha and delta nAb titers were significantly lower in patients with MM compared with those in controls (Figure 1D). Among patients with MM, anti-CD38 therapy further reduced nAb production against the alpha variant, with a near-significant trend for the delta variant (Figure 1E). In patients with MM, we observed a low correlation between anti-S IgG or IgA and anti-alpha or -delta




Figure 1.




Figure 2. Impact of SARS-CoV-2 infection on immunologic response to BNT162b2 in patients with MM. (A-C) Patients with MM with a history of infection with SARS-CoV-2 (more than 3 months before vaccination) who developed their infection at any time after vaccination or who had never had SARS-CoV-2 infection. (A) S-Flow IgG quantification (history of SARS-CoV-2 infection, $n = 11$; post-vaccine SARS-CoV-2, $n = 4$; other, $n = 56$). (B) Alpha (left) or delta (right) nAb quantification (history of SARS-CoV-2 infection, $n = 11$; post-vaccine SARS-CoV-2, $n = 4$; other, $n = 56$). (C) S1 (left) or S2 (right) IFN- γ EliSpot (SARS-CoV-2 history, $n = 5$; other, $n = 21$). Error bars represent standard error. * $P < .05$; *** $P < .001$; **** $P < .0001$. ns, not significant.

nAb production, chiefly because patients developed IgG or IgA but not nAbs (supplemental Figure 1E).

We investigated the humoral response on day 21 in 16 patients with MM who were in the anti-CD38 group and who received a third dose of BNT162b2 at least 21 days after the second dose (booster protocol). We observed an improvement in the S response in half the patients who had achieved seroconversion to the second dose (Bethesda units [BU] >0.6) and a significant increase in IgG titers in patients with suboptimal response (BU <0.6) (supplemental Figure 2A). However, no significant improvement of alpha or delta nAb response was observed even if increased nAbs were observed in some patients (supplemental Figure 2B).

Finally, we observed that an absence of neutralizing response against alpha and delta variants after the second dose was significantly associated with progressive disease, number of treatment lines, and lower gammaglobulin levels, and that anti-CD38 therapy was associated with failure to generate nAbs (supplemental Table 2). However, none of these variables retained statistical significance after multivariable analysis, possibly because of the limited number of patients included in the study or the interactions between variables. Because patients with MM who were treated or not treated with anti-CD38 received immunomodulatory imide drugs or proteasome inhibitors in similar proportions, our results suggest that impaired immune response to SARS-CoV-2 vaccine is favored by targeting nonmalignant B cells, as reported in patients receiving anti-CD20 antibodies.⁶⁻⁸

Figure 1. Impaired humoral and cellular response to BNT162b2 in patients with MM. (A) Flowchart of the study. BNT162b2 anti-SARS-CoV-2 vaccine was used in this study; 2 doses were administered 4 weeks apart. In all, 16 patients (from the anti-CD38 group) received a third booster vaccine dose. The anti-CD38 group is defined as patients who were treated with anti-CD38 immunotherapy. The convalescent group is defined as patients with a history of SARS-CoV-2 infection who were given the vaccine. T0 is the time before vaccine, M1 is 1 month after the first vaccine dose, and M3 is 3 months after the first vaccine dose. (B-C) SARS-CoV-2-specific IgG and IgA production quantified by S-Flow in 60 patients with MM who had never been infected with SARS-CoV-2 and 23 healthy volunteers. (B) IgG (left panel) and IgA (right panel) quantification in controls or patients with MM before vaccination (T0) and at M1 and M3. (C) Comparison of IgG amounts in patients with MM who were treated or not treated with anti-CD38 immunotherapy. (D-E) Quantification of anti-SARS-CoV-2 nAbs against alpha or delta variants in controls ($n = 23$) or patients with MM ($n = 60$). (D) Comparison between controls and patients with MM. (E) Comparison between patients receiving or not receiving anti-CD38 immunotherapy. (F) Quantification of cellular immune response by S1 or S2 EliSpot (in spot forming units, SFU, per 10^6 CD3 cells) in controls ($n = 21$) or patients with MM ($n = 26$). Patients receiving anti-CD38 immunotherapies are indicated. Error bars represent standard error. * $P < .05$; ** $P < .01$; *** $P < .001$; **** $P < .0001$. ns, not significant.

We investigated anti-SARS-CoV-2 T-cell response after vaccination in 26 patients with MM from our cohort, including 24 who received anti-CD38 therapy and 21 healthy volunteers 3 months after the first dose of BNT162b2. The IFN- γ production by T cells after stimulation with S1 or S2 antigens ex vivo was significantly lower in patients with MM compared with that in healthy controls who had never been infected by SARS-CoV-2 (Figure 1F). Among 26 patients with MM tested for cellular response, 12 (46%) lacked nAbs and IFN- γ production, 5 (19%) developed both humoral and cellular response, and 9 (35%) showed heterogeneous results (supplemental Figure 3). Notably, all controls had both nAbs and specific T-cell response after vaccination with BNT162b2 (data not shown). These results show an altered cellular response to anti-SARS-CoV-2 vaccine in patients with MM.

Next, we studied the immune response to BNT162b2 that depended on patients having a history of SARS-CoV-2 infection. First, we observed higher anti-S IgG levels in patients with MM who had a history of SARS-CoV-2 infection before ($n = 11$) or after ($n = 4$) vaccination compared with other patients, with no differences regarding the timing of infection or vaccination (Figure 2A). Similarly, patients with MM who were infected with SARS-CoV-2 had higher alpha- and delta-specific nAb levels and T-cell IFN- γ response compared with those who had not been infected (Figure 2B-C).

Among our cohort of 60 patients with MM who had never been infected with SARS-CoV-2, 4 developed an infection after 1 dose ($n = 2$) or 2 doses ($n = 2$) of BNT162b2, and all were receiving anti-CD38 immunotherapy (Figure 1A). We retrospectively recorded mortality related to SARS-CoV-2 from January 2020 to July 2021 in 39 public hospitals in Paris, France, using the Informatics for Integrated Biology and the Bedside (i2b2) platform. When comparing 2 epidemic peak periods (March to July 2020 and March to July 2021), the number of deaths related to SARS-CoV-2 infection remained stable or tended to decrease in patients with MM who were or were not receiving anti-CD38 immunotherapy, respectively, even though anti-CD38 prescription volume remained stable (supplemental Figure 4A-B). Although several biases could have occurred in this retrospective multisite analysis, these results along with our observations in a small cohort suggest that impaired vaccine response in patients receiving anti-CD38 could have clinical implications that should be investigated prospectively.

In contrast to observations made among healthy populations,^{3,9} correlation between the commonly used S-Flow antibody titration technique and the detection of nAbs was weak in patients with MM, suggesting a low predictive value of serology in terms of protection. Moreover, emergence of SARS-CoV-2 variants with lower response to vaccination, such as the delta variant is particularly problematic for individuals with suboptimal vaccine response.^{3,10} In agreement with recent reports, we observed heterogeneous humoral response to vaccine in patients with MM who had never been infected with SARS-CoV-2.¹¹ Patients with MM who were treated with anti-CD38 immunotherapy remain at higher risk of SARS-CoV-2 infection after mRNA-based vaccination compared with patients who receive alternative therapies.¹² In contrast, patients with MM who became infected with SARS-CoV-2 before or after vaccination had homogeneous and robust immune response. Our preliminary

results on booster vaccination also suggest that immune response to SARS-CoV-2 remains actionable in patients with MM. Improvement of vaccine formulation such as adjuvant use or heterologous vaccination procedure¹³ should be considered in this frail population.

Acknowledgments

The authors thank the patients and the healthy volunteers who participated in this study and all nurses, technicians, and physicians from Groupe Hospitalo-Universitaire AP-HP.CUP involved in the daily care of the patients included or not included in this study; they have gone far beyond their usual jobs during this epidemic.

This study was supported by Fonds IMMUNOV for Innovation in Immunopathology, by the Institut Pasteur (for work in the OS laboratory), the Urgence COVID-19 Fundraising Campaign of Institut Pasteur, Fondation pour la Recherche Médicale, and ANRS, and by grants from the Vaccine Research Institute (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), ANR/FRM Flash Covid PROTEO-SARS-CoV-2, and IDISCOVER. D.P. is supported by the Vaccine Research Institute.

Authorship

Contribution: S.H., J.Z., T.B., A.O., and D.P. designed the study, collected and analyzed data, and wrote the manuscript; T.B., A.O., D.P., and I.S. designed and performed experiments; P.D., J.H., B.V., N.E., D.B., L.W., G.F., J.D., P.F., and B.D.-F. provided care for the patients; B.T. and J.T. analyzed data and wrote the manuscript; L.C. and O.S. designed and supervised experiments and wrote the manuscript; and M.V. designed and supervised the study, analyzed data, and wrote the manuscript.

Conflict-of-interest disclosure: T.B., I.S., and O.S. are co-inventors on a provisional patent (US 63/020063) entitled "S-Flow: a FACS-based assay for serological analysis of SARS-CoV-2 infection" submitted by Institut Pasteur. The remaining authors declare no competing financial interests.

ORCID profiles: S.H., 0000-0003-2368-4292; T.B., 0000-0002-3952-4261; D.P., 0000-0002-2509-9954; J.T., 0000-0002-0167-5996; O.S., 0000-0002-0729-1475.

Correspondence: Marguerite Vignon, Department of Clinical Hematology, Hôpital Cochin, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France; e-mail: marguerite.vignon@aphp.fr.

Footnotes

Submitted August 13, 2021; accepted November 20, 2021; prepublished online on *Blood* First Edition December 14, 2021.

*S.H., J.Z., T.B., and A.O. contributed equally to this study.

For original data, please contact Soledad Henriquez via email at soledad.henriquez@aphp.fr.

The online version of this article contains a data supplement.

REFERENCES

- European Society for Medical Oncology. ESMO Statements on vaccination against COVID-19 in people with cancer. <https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination>. Accessed 24 June 2021.
- Terpos E, Zagouri F, Liontos M, et al. Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. *J Hematol Oncol*. 2021;14(1):86.

3. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. *Nature*. 2021;596(7871):276-280.
4. Grzelak L, Temmam S, Planchais C, et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. *Sci Transl Med*. 2020;12(559):eabc3103.
5. Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. *Nat Med*. 2021;27(5):917-924.
6. Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. *Ann Rheum Dis*. 2021;80(10):1357-1359.
7. Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. *Ann Rheum Dis*. 2021;80(10):1355-1356.
8. Addeo A, Shah PK, Bordry N, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. *Cancer Cell*. 2021;39(8):1091-1098.e2.
9. Stamatatos L, Czartoski J, Wan Y-H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection [published online ahead of print 25 March 2021]. *Science*.
10. Ying B, Whitener B, VanBlargen LA, et al. Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains [published online ahead of print 26 August 2021]. *bioRxiv*.
11. Van Oekelen O, Gleason CR, Agte S, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. *Cancer Cell*. 2021;39(8):1028-1030.
12. Pimpinelli F, Marchesi F, Piaggio G, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. *J Hematol Oncol*. 2021;14(1):81.
13. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *Nat Med*. 2021;27(9):1525-1529.

DOI 10.1182/blood.2021013714

© 2022 by The American Society of Hematology

TO THE EDITOR:

Redefining nonmeasurable multiple myeloma using mass spectrometry

Hannah V. Giles,^{1,2} Mark A. Cook,^{2,3} Mark Trehane Drayson,⁴ Gordon Cook,^{5,6} Nicola Jane Wright,⁷ Simon John North,⁷ Stephen Harding,⁷ David A. Cairns,⁶ Anna Hockaday,⁶ Martin F. Kaiser,⁸ Paul Moss,^{1,2} Faith E. Davies,⁹ Gareth J. Morgan,¹⁰ Graham Jackson,^{11,12} and Guy Pratt^{1,2}

¹University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; ²University of Birmingham, Birmingham, United Kingdom; ³Bristol Myers Squibb, Boudry, Switzerland; ⁴Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom; ⁵St James's Institute of Oncology, Leeds, United Kingdom; ⁶Cancer Research UK Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom; ⁷The Binding Site Ltd, Birmingham, United Kingdom; ⁸The Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom; ⁹Perlmutter Cancer Center and ¹⁰Department of Hematology, NYU Langone Health Care, New York, NY; ¹¹Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom; and ¹²Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

In most patients with multiple myeloma, the neoplastic plasma cells produce a monoclonal immunoglobulin, which can be measured in the serum and urine and serves as a biomarker to aid diagnosis and assess response. However, 1% to 3% of patients produce no detectable paraprotein and are described as having nonsecretory multiple myeloma (NSMM).¹⁻⁵ A further 2% to 3% of patients have insufficient levels of paraprotein production for reliable serological monitoring of their treatment response^{5,6} and are described as having nonmeasurable oligo-secretory multiple myeloma (OSMM) (paraprotein <10 g/L, Bence Jones protein <200 mg/24 h, and involved serum free light chain [iFLC] <100 mg/L⁴). The gold standard for monitoring patients with nonmeasurable myeloma (NMM) is serial bone marrow biopsies⁴ but this is an invasive and often painful procedure. In real-world practice, many patients with NMM are monitored with serial imaging. However, there are limitations in availability and repeated exposure to high doses of radiation with serial positron emission tomography-computed tomography scans. Patients with NMM are challenging to diagnose and monitor and are frequently excluded from clinical trials, limiting their access to novel agents.

Mass spectrometry (MS) methodologies are emerging as a new and more sensitive way to monitor paraprotein levels in serum.⁷⁻¹² They have recently been approved by the International Myeloma Working Group for use in lieu of immunofixation¹³ and have the advantage that they can quantitate low-level paraproteins.⁷ Preliminary studies have reported that the limit of detection for matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS is <10 mg/L.¹⁴ In this study, we investigated how many patients with NSMM have detectable paraprotein production using MALDI-TOF MS and the suitability of MS for monitoring patients with NMM.

MS analysis was performed on all available presentation and follow-up samples from patients with NSMM (immunofixation negative and iFLC <100 mg/L) and OSMM from during induction and up to day+100 after autologous stem cell transplantation (ASCT) from patients treated in the Myeloma XI trial. The baseline characteristics of these patients are listed in Table 1. The methods for the MS analysis have been described previously.^{7,14,15} Paraprotein detection rates were compared with the serum protein electrophoresis (SPE), immunofixation, and Free-lite results.